TY - JOUR
T1 - Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice
AU - Metcalfe, John Z.
AU - Cattamanchi, Adithya
AU - McCulloch, Charles E.
AU - Lew, Justin D.
AU - Ha, Ngan P.
AU - Graviss, Edward A.
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2013/1/15
Y1 - 2013/1/15
N2 - Rationale: Although IFN-γ release assays (IGRAs) are widely used to screen for Mycobacterium tuberculosis infection in high-income countries, published data on repeatability are limited. Objectives: To determine IGRA repeatability. Methods: The study population included consecutive patients referred to The Methodist Hospital (Houston, TX) between August 1, 2010 and July 31, 2011 for latent tuberculosis (TB) infection screening withanIGRA(QuantiFERON-TBGoldIn-Tube;Cellestis,Carnegie, Australia). We performed multiple IGRA tests using leftover stimulated plasma according to a prospectively formulated quality control protocol. We analyzed agreement in interpretation of test results classified according to manufacturer-recommended criteria and repeatability of quantitative TB response. Measurements and Main Results: During the study period, 1,086 test results were obtained from 543 subjects. Per the manufacturer's cutpoint, the result of the second test was discordant from that of the first in 28 (8%) of 366 patients with valid test results, including 13 with an initial negative result and 15 with an initial positive result. Although agreement between repeat test results was high (k=0.84; 95% confidence interval, 0.79-0.90), the normal expected range of within-subject variability in TB response on retesting included differences of ± 0.60 IU/ml for all individuals (coefficient of variation, 14%),and±0.24 IU/ml (coefficientof variation,27%)for individuals whose initial TB response was between 0.25 and 0.80 IU/ml. Conclusions: There is substantial variability in TB response when IGRAs are repeated using the same patient sample. IGRA results should be interpreted cautiously when TB response is near interpretation cut-points.
AB - Rationale: Although IFN-γ release assays (IGRAs) are widely used to screen for Mycobacterium tuberculosis infection in high-income countries, published data on repeatability are limited. Objectives: To determine IGRA repeatability. Methods: The study population included consecutive patients referred to The Methodist Hospital (Houston, TX) between August 1, 2010 and July 31, 2011 for latent tuberculosis (TB) infection screening withanIGRA(QuantiFERON-TBGoldIn-Tube;Cellestis,Carnegie, Australia). We performed multiple IGRA tests using leftover stimulated plasma according to a prospectively formulated quality control protocol. We analyzed agreement in interpretation of test results classified according to manufacturer-recommended criteria and repeatability of quantitative TB response. Measurements and Main Results: During the study period, 1,086 test results were obtained from 543 subjects. Per the manufacturer's cutpoint, the result of the second test was discordant from that of the first in 28 (8%) of 366 patients with valid test results, including 13 with an initial negative result and 15 with an initial positive result. Although agreement between repeat test results was high (k=0.84; 95% confidence interval, 0.79-0.90), the normal expected range of within-subject variability in TB response on retesting included differences of ± 0.60 IU/ml for all individuals (coefficient of variation, 14%),and±0.24 IU/ml (coefficientof variation,27%)for individuals whose initial TB response was between 0.25 and 0.80 IU/ml. Conclusions: There is substantial variability in TB response when IGRAs are repeated using the same patient sample. IGRA results should be interpreted cautiously when TB response is near interpretation cut-points.
KW - Imprecision
KW - Interferon-γ release assay
KW - QuantiFERON
KW - Repeatability
UR - http://www.scopus.com/inward/record.url?scp=84872583104&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872583104&partnerID=8YFLogxK
U2 - 10.1164/rccm.201203-0430OC
DO - 10.1164/rccm.201203-0430OC
M3 - Article
C2 - 23103734
AN - SCOPUS:84872583104
SN - 1073-449X
VL - 187
SP - 206
EP - 211
JO - American journal of respiratory and critical care medicine
JF - American journal of respiratory and critical care medicine
IS - 2
ER -